Q BioMed wins federal contract for bone cancer drug

Q BioMed (OTCQB:QBIO) announced today that it signed an agreement for its Strontium89 drug to be included on the Federal Supply Schedule (FSS).

New York-based Q BioMed’s agreement with the U.S. government provides U.S. veterans and other federal government agencies and eligible patients access to Strontium89, a treatment for metastatic bone pain related to common cancers, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0